Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Nordic people know how to beat the winter blues. Here's how to find light in the darkest months - 2Figure out How to Streamline Your Profits in Gold Speculation
- 3Toddler diagnosed with cancer makes remarkable recovery after aggressive treatment
- 4Family Holiday spots
- 5Private sector revives the climate disaster database Trump tried to squash
- The Best Portable Applications for Emotional wellness and Prosperity
- Kremlin: Russian troops conquer Pokrovsk after year of intense combat
- Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
- Step by step instructions to Protect Your Speculations with Cd Rates
- Focus on Yourself: Wellbeing and Taking care of oneself Practices
- Gaza humanitarian efforts reach key milestone as UNICEF vaccinates some 13,000 children
- Doritos and Cheetos dial back the bright orange in new versions without artificial ingredients
- Which Kind of Pet Makes the Incomparable Buddy?
- Figure out How to Ascertain the Restitution Time frame for Your Sunlight based chargers
